Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prevnar 13 Post-Market Trials Must Confirm Surrogate Endpoint, Deal With Immunogenicity

Executive Summary

New post-marketing commitment will look at conjugate pneumonia vaccine when given in patients 50 and older who have already received Merck’s polysaccharide vaccine.

You may also be interested in...



Vaccine Biomarkers: Don't Put Cart Before Horse When Designing Studies, US FDA Advises

If a sponsor wants to use a biomarker to show vaccine effectiveness, it should first explain why a clinical endpoint study is not feasible, US FDA official advises.

Prevnar 13 Loses ‘Routine’ Endorsement For Older Adults In CDC Panel Vote

ACIP still supports use of Pfizer’s pneumococcal vaccine in immunocompetent individuals ages 65 years and older based on shared clinical decision-making, but concludes that routine immunization is no longer warranted due to herd effect from pediatric vaccination.

Prevnar 13 Recommendation For Medicare Population May Be Short Lived

CDC advisory committee support for Pfizer pneumococcal vaccine in adults 65 and older comes with caveat that recommendation will be re-examined, and possibly revised, in 2018 due to effects of herd immunity.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054086

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel